Acromegaly is associated with many comorbidities and increased mortality. The first-line treatment is transsphenoidal surgery. However, many patients also need adjuvant drug treatment after surgery. Somatostatin analog (SSA), which suppresses GH secretion by somatotrophs by binding to the SSTR2 receptor, is the first choice. Nevertheless, 50% of patients are partially or totally resistant to SSA, so predictive factors of response are helpful to individualize drug treatment. 68GaDOTATATE PET/CT has emerged as the gold-standard method in the diagnosis and follow-up of gastroenteropancreatic neuroendocrine tumors, which also express SSTR. Our objective was to evaluate whether 68Ga-DOTATATE uptake (SUV max) at the pituitary region of patients on SSA therapy would be useful as a drug response predictor without the need of tumoral tissue.
Fifteen acromegalics patients on SSA treatment for at least 6 months were underwent to 68Ga-DOTATATE PET/CT at the nuclear medicine service. There was an SSA complete response group (n = 5), defined as GH < 1 µg/L and IFG-1 in the normal range for gender and age, and a group that did not meet these criteria (n = 10).
As a result, we did not find out a significantly higher SUV max in the complete response group (p = 0.0576) to SSA. However, we found a significant inverse relationship between postoperative GH values and the SUVmax at the sella turcica (p = 0.0188), probably reflecting tumor SSTR2 expression.
Thus, after this initial evaluation, 68GaDOTATATE PET/CT should be better studied to assess its usefulness in the follow-up of acromegalic patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951
Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS (2018) Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 179(1):59–71
Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A Consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552–561
Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R (2019) Acromegaly. Nat Rev Dis Primers 5(1):20
Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100(1):122–131
Paragliola RM, Corsello SM, Salvatori R (2017) Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary 20(1):109–115
Tortora F, Negro A, Grasso LFS, Colao A, Pivonello R, Splendiani A, Brunese L, Caranci F (2019) Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas. Gland Surg 8(Suppl 3):S150–S158
Potorac I, Beckers A, Bonneville JF (2017) T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. Pituitary 20(1):116–120
Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Centeno RG, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJ, Delemer B, Petit JM, Schöfl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23(11):871881
Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490–498
Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC (2016) Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med 57(5):708–714
Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112(11):2447–2455
Conover WJ (1999) Practical nonparametric statistics, 3a edn. John Wiley & Sons Inc., Nova Iorque
Fleiss JL (1981) Statistical methods for rates and proportions, 2a edn. John Wiley & Sons Inc., Nova Iorque
Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D (2017) Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 20(1):100–108
Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, Subramaniam RM (2018) Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET/CT. Am J Roentgenol 211(2):267–277
Cremonini N, Furno A, Sforza A, Chiarini V, Graziano E, Zampa G, Turba E (1995) 111Inoctreotide scintigraphy in endocrine tumors. Preliminary data. Q J Nucl Med 39(4 Suppl 1):116–120
Tirosh A, Kebebew E (2018) The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol 14(2):111–122
Ito T, Jensen RT (2017) Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes 24(1):15–24
Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M, Lombardi G (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81(6):2356–2362
Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, Attanasio R, Milella M, Banfi G, Possa M (1998) Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors. J Endocrinol Invest 21(8):5129
Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ (1997) Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 136(4):369–376
Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ (1994) Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79(5):1416–1423
Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N (1997) Indiumpentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients. J Endocrinol Invest 20(7):424–428
Coura-Filho GB, Hoff AAFO, Duarte PS, Buchpiguel CA, Josefsson A, Hobbs RF, Sgouros G, Sapienza MT (2019) 68Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours. Nucl Med Commun 40(9):920–926
Iglesias P, Cardona J, Díez JJ (2019) The pituitary in nuclear medicine imaging. Eur J Intern Med 68:6–12
Waligórska-Stachura J, Gut P, Sawicka-Gutaj N, Liebert W, Gryczyńska M, Baszko-Błaszyk D, Blanco-Gangoo AR, Ruchała M (2016) Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report. J Neurosurg 125(2):346–349
d’Amico A, Stąpór-Fudzińska M, Tarnawski R (2014) CyberKnife radiosurgery planning of a secreting pituitary adenoma performed with 68Ga DOTATATE PET and MRI. Clin Nucl Med 39(12):1043–1044
Wang H, Hou B, Lu L, Feng M, Zang J, Yao S, Feng F, Wang R, Li F, Zhu Z (2018) PET/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study. J Nucl Med 59(3):523–528
Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189–3202
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A (2010) Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68GaDOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37(10):2004–2010
Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG (2002) Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 146(3):295–302
Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocr Metab 98(11):E1730–E1739
Koulouri O, Kandasamy N, Hoole AC, Gillett D, Heard S, Powlson AS, O’Donovan DG, Annamalai AK, Simpson HL, Akker SA, Aylwin SJ, Brooke A, Buch H, Levy MJ, Martin N, Morris D, Parkinson C, Tysome JR, Santarius T, Donnelly N, Buscombe J, Boros I, Smith R, Aigbirhio F, Antoun NM, Burnet NG, Cheow H, Mannion RJ, Pickard JD, Gurnell M (2016) Successful treatment of residual pituitary adenoma in persistent acromegaly following localization by 11C-methionine PET co-registered with MRI. Eur J Endocrinol 175(5):485–498
We did not receive any funding for this survey. 68Ga-DOTATATE doses were donated by the Institute of Energy and Nuclear Research (IPEN).
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
The Ethics Committee on Research approved the study in Human Beings under number 70882317.4.0000.5404. Written informed consents were obtained from all participants.
The participating subjects provided the written informed consent.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Daniel, K.B., de Oliveira Santos, A., de Andrade, R.A. et al. Evaluation of 68Ga-DOTATATE uptake at the pituitary region and the biochemical response to somatostatin analogs in acromegaly. J Endocrinol Invest (2021). https://doi.org/10.1007/s40618-021-01523-6
- Somatostatin analogs